Research on glutamatergic neurotransmission has focused mainly on the function of
presynaptic and postsynaptic neurons, leaving astrocytes with a secondary role only to …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

Introduction Symptoms of schizophrenia are closely related to aberrant language
comprehension and production. Macroscopic brain changes seen in some patients with …

Background: Dysfunction of the N-methyl-D-aspartate glutamate receptor is involved in the
putative pathology of schizophrenia. There is growing interest in the potential of N-methyl-D …

Schizophrenia continues to be an illness with poor outcome. Most mechanistic changes
occur many years before the first episode of schizophrenia; these are not reversible after the …

Background: Abnormalities in the anterior cingulate cortex (ACC) are thought to play an
important role in the pathophysiology of schizophrenia. Given regional variations in ACC …

A large proportion of patients with schizophrenia exhibit deficits in cognitive control functions
including working memory, processing speed and inhibitory control, which have been …

This systematic review aimed to review neuroimaging studies comparing clozapine-resistant
schizophrenia patients with clozapine-responding patients, and with first-line antipsychotic …

Abstract Treatment-Resistant Schizophrenia (TRS) represents a main clinical issue,
associated with worse psychopathological outcomes, a more disrupted neurobiological …

Introduction Recent studies have observed that patients with treatment-resistant
schizophrenia as well as patients with schizophrenia who do not respond within a …